Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group | MicrobiomeTrials← Back to trialsNCT05754593
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2023-12-04Est. Completion: 2027-12
Enrollment target: 160 participants Locations- CHU de Bordeaux - service de neurologie, Bordeaux, France
Other microbiome trials you might be interested in
B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-c…
La Jolla, United StatesEst. completion Dec 1, 2026
Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multi…
Birmingham, United StatesEst. completion May 26, 2027
Phase 3
Recruiting
Multiple Sclerosis (MS) Primary Progressive
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicente…
Pheonix, United StatesEst. completion Jun 2030